Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGE-A1 + MAGE-A3 + NY-ESO-1 peptide-pulsed dendritic cell vaccine
- Development stage
- Phase 1
- Lead developer
- Miyazaki University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
This MAGE-A1 + MAGE-A3 + NY-ESO-1 peptide-pulsed dendritic cell vaccine is an autologous cellular immunotherapy designed to induce a specific immune response against malignancies expressing cancer-testis (CT) antigens. The production process involves harvesting a patient's peripheral blood mononuclear cells via leukapheresis, differentiating them into immature dendritic cells (DCs) ex vivo using cytokines like GM-CSF and IL-4, and subsequently pulsing these DCs with human leukocyte antigen (HLA)-restricted peptides derived from MAGE-A1, MAGE-A3, and NY-ESO-1. These mature, antigen-loaded dendritic cells are then re-administered to the patient, typically via intradermal or subcutaneous injection. Once in vivo, these professional antigen-presenting cells migrate to regional lymph nodes to prime and activate naive CD8+ T-cells into antigen-specific cytotoxic T-lymphocytes (CTLs). These effector CTLs then circulate and target tumor cells that display the corresponding peptide-MHC complexes on their surface, leading to targeted tumor cell lysis.
- Other names
- MAGE-A1, MAGE-A3, and NY-ESO-1 peptide-pulsed autologous dendritic cell vaccineMAGE-A1/A3/NY-ESO-1 pulsed DC vaccineAutologous dendritic cells pulsed with MAGE-A1, MAGE-A3, and NY-ESO-1 peptides
02
Targets
MAGEA1 (Melanoma-associated antigen 1)MAGEA3 (Melanoma-associated antigen 3)NY-ESO-1 (New york esophageal squamous cell carcinoma 1)
Beyond the preview
Go deeper on MAGE-A1 + MAGE-A3 + NY-ESO-1 peptide-pulsed dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-A1 + MAGE-A3 + NY-ESO-1 peptide-pulsed dendritic cell vaccine.